GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) but their most recent incarnations, which consist of both next generation GLP-1s and combinations (Ozempic, Mounjaro, Wegovy, Zepbound), have moved beyond the realm of T2D into the treatment of obesity
Nausea, constipation, and reduced appetite are common initially but usually decrease as your body adjusts
Synthesis and Quality Assurance: BPC-157 is meticulously synthesised through a controlled process that guarantees high purity and stability, making it suitable for precise scientific studies
Variants in the GLP1R gene (like rs6923761), GIPR gene (rs1800437), and FTO gene (rs9939609) affect how efficiently your cells bind and respond to GLP-1 and GIP signaling
in the New England Journal of Medicine in 2023